BYSI — BeyondSpring Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1677940 ·
Last close
$0.61
Market Cap
$25.04M
52W High
$2.44
52W Low
$0.57
ADV30
443,010
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,731,000 | -849,000 | 14,606,000 | 2,697,000 | 50,631,000 |
| Mar 2026 | 0 | — | -2,232,000 | -2,159,000 | 18,406,000 | 4,036,000 | 48,760,000 |
| Dec 2025 | 0 | — | -2,596,000 | -2,137,000 | 25,933,000 | 7,786,000 | 49,923,000 |
| Sep 2025 | 0 | — | -1,790,000 | -1,540,000 | 29,484,000 | 12,483,000 | 49,294,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,848,000
Investing CF
$8,962,000
Financing CF
$811,000
CapEx
$-77,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.02
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-410,590,000
Inventory
—
Receivables
—
ST Investments
$3,827,000
EBIT TTM
$-8,567,000
Pretax Income TTM
$-8,220,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,945,000 | -1,006,000 | 25,933,000 | 49,923,000 | -32,161,000 | -19,769,000 |
| Dec 2024 | 0 | -8,754,000 | -11,123,000 | 34,315,000 | 48,600,000 | -32,900,000 | -16,443,000 |
| Dec 2023 | 0 | -15,081,000 | -21,026,000 | 24,808,000 | 48,269,000 | -26,805,000 | -16,474,000 |
| Dec 2022 | 1,351,000 | -37,239,000 | -33,279,000 | 46,222,000 | 49,229,000 | -5,979,000 | -28,151,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-7,642,000
OpCashFlow TTM
—
Assets (Latest)
$18,406,000
Forward EPS
$-0.47
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATOS | ATOSSA THERAPEUTICS, INC. | $24.15M | $2.42 | — |
| KYNB | KYNTRA BIO, INC. | $24.13M | $5.96 | — |
| ABVC | ABVC BIOPHARMA, INC. | $26.12M | $0.98 | — |
| MCRB | Seres Therapeutics, Inc. | $26.42M | $2.63 | — |
| ETST | Earth Science Tech, Inc. | $26.60M | $0.09 | — |
News headlines (Yahoo Finance, 1h cache)
BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances
2026-09-29 14:43 · Yahoo
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
2026-09-29 11:01 · Yahoo
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
2026-08-14 21:15 · Yahoo
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
2026-06-04 11:00 · Yahoo
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
2026-05-18 11:00 · Yahoo
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 11:00 · Yahoo
Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
2026-04-06 10:41 · Yahoo
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
2026-04-22 11:00 · Yahoo
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
2026-03-30 11:30 · Yahoo
BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)
2026-05-13 13:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.